Xianglong Zong1, Jie Zhang1, Xin Ji1, Jie Gao1, Jiafu Ji1. 1. 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 China Health Insurance Research Association, Beijing 100013, China ; 3 MSD China Holding Co., Ltd., Shanghai 200040, China.
Abstract
BACKGROUND: Few studies have attempted to evaluate the use of antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) at a national level in China or to assess how treatment regimens adhere to current guidelines. METHODS: We searched the China Health Insurance Research Association (CHIRA) Database to identify patients with cancer who were ≥18 years old and received either moderately or highly emetogenic chemotherapy (MEC and HEC, respectively) between 2008 and 2012. Patients' characteristics as well as usage of specific antiemetic regimens were analyzed using descriptive statistics. RESULTS: Of the 14,548 patients included in the study, 6,477 received HEC while 8,071 were treated with MEC. Approximately 89.9% used antiemetics prophylactically to prevent acute CINV and 71.5% for delayed CINV while 9.0% were prescribed antiemetics as rescue therapy. A significantly lower proportion of patients treated with HEC received prophylactic antiemetic therapy for delayed CINV as compared to those treated with MEC (59.4% vs. 81.3%; P<0.001). The HEC group had a slightly lower proportion of patients using a mixed regimen containing a 5-HT3 antagonist to prevent both acute and delayed CINV than the MEC group (P≤0.012); however, a higher proportion received a mixed regimen containing corticosteroids (P≤0.007). Although more than half of the patients in the HEC group took three antiemetics to prevent acute and delayed CINV, these rates were significantly lower than those of the MEC group (both P<0.001). Finally, analysis of the regimens used revealed that there is over-utilization of drugs within the same class of antiemetic. CONCLUSIONS: These findings indicate that more attention is needed for treatment of delayed CINV, in terms of both overall use and the components of a typical treatment regimen.
BACKGROUND: Few studies have attempted to evaluate the use of antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) at a national level in China or to assess how treatment regimens adhere to current guidelines. METHODS: We searched the China Health Insurance Research Association (CHIRA) Database to identify patients with cancer who were ≥18 years old and received either moderately or highly emetogenic chemotherapy (MEC and HEC, respectively) between 2008 and 2012. Patients' characteristics as well as usage of specific antiemetic regimens were analyzed using descriptive statistics. RESULTS: Of the 14,548 patients included in the study, 6,477 received HEC while 8,071 were treated with MEC. Approximately 89.9% used antiemetics prophylactically to prevent acute CINV and 71.5% for delayed CINV while 9.0% were prescribed antiemetics as rescue therapy. A significantly lower proportion of patients treated with HEC received prophylactic antiemetic therapy for delayed CINV as compared to those treated with MEC (59.4% vs. 81.3%; P<0.001). The HEC group had a slightly lower proportion of patients using a mixed regimen containing a 5-HT3 antagonist to prevent both acute and delayed CINV than the MEC group (P≤0.012); however, a higher proportion received a mixed regimen containing corticosteroids (P≤0.007). Although more than half of the patients in the HEC group took three antiemetics to prevent acute and delayed CINV, these rates were significantly lower than those of the MEC group (both P<0.001). Finally, analysis of the regimens used revealed that there is over-utilization of drugs within the same class of antiemetic. CONCLUSIONS: These findings indicate that more attention is needed for treatment of delayed CINV, in terms of both overall use and the components of a typical treatment regimen.
Entities:
Keywords:
Adherence; antiemetics; chemotherapy-induced nausea and vomiting (CINV); prescription
Authors: David S Ettinger; Debra K Armstrong; Sally Barbour; Michael J Berger; Philip J Bierman; Bob Bradbury; Georgianna Ellis; Steve Kirkegaard; Dwight D Kloth; Mark G Kris; Dean Lim; Laura Boehnke Michaud; Lida Nabati; Kim Noonan; Hope S Rugo; Darby Siler; Steven M Sorscher; Sundae Stelts; Lisa Stucky-Marshall; Barbara Todaro; Susan G Urba Journal: J Natl Compr Canc Netw Date: 2012-04 Impact factor: 11.908
Authors: John M Salsman; Steven M Grunberg; Jennifer L Beaumont; Miriam Rogers; Diane Paul; Marla L Clayman; David Cella Journal: J Natl Compr Canc Netw Date: 2012-02 Impact factor: 11.908
Authors: Chantal Quinten; Francesca Martinelli; Corneel Coens; Mirjam A G Sprangers; Jolie Ringash; Carolyn Gotay; Kristin Bjordal; Eva Greimel; Bryce B Reeve; John Maringwa; Divine E Ediebah; Efstathios Zikos; Madeleine T King; David Osoba; Martin J Taphoorn; Henning Flechtner; Joseph Schmucker-Von Koch; Joachim Weis; Andrew Bottomley Journal: Cancer Date: 2013-10-11 Impact factor: 6.860
Authors: Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow Journal: Expert Opin Pharmacother Date: 2013-04 Impact factor: 3.889
Authors: A Molassiotis; M P Saunders; J Valle; G Wilson; P Lorigan; A Wardley; E Levine; R Cowan; J Loncaster; C Rittenberg Journal: Support Care Cancer Date: 2007-10-10 Impact factor: 3.603
Authors: D A Perwitasari; Hans Gelderblom; Jarir Atthobari; Mustofa Mustofa; Iwan Dwiprahasto; Johan W R Nortier; Henk-Jan Guchelaar Journal: Int J Clin Pharm Date: 2011-01-28
Authors: Kednapa Thavorn; Doug Coyle; Jeffrey S Hoch; Lisa Vandermeer; Sasha Mazzarello; Zhou Wang; George Dranitsaris; Dean Fergusson; Mark Clemons Journal: Support Care Cancer Date: 2017-03-09 Impact factor: 3.603
Authors: Gayathri Baburaj; Ansha Mariya Abraham; Lija George; Vijith Shetty; Rovin M Thempalangad; K S Rajesh; K C Bharath Raj Journal: Indian J Med Paediatr Oncol Date: 2017 Jul-Sep